The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...

Me is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing ...

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...

23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.